A retrospective study conducted in RA patients with and without diabetes revealed that TNF inhibitors and TCZ led to significantly lower HbA1c values at 1 month and 3 months after treatment initiation, with significant changes in HbA1c values persisting in each group regardless of the presence of diabetes [188]. The gene discussed is TNF; the disease is rheumatoid arthritis.